Home Companies Catalysts Deep Dives
Kesimpta ofatumumab APPROVED
Drug Profile
ModalityAntibody
RouteSC
Therapy AreaNeurology
Launch2020-08-20
US LOE2035-08-15
Peak Sales Est$6900M
Formulations[{"id":"kesimpta-sc","doses":"20mg","route":"SC","device":"Sensoready pen","setting":"PATIENT_SELF",
Companies
NVS (ORIGINATOR)100%
GMAB (ORIGINATOR)0%
Mechanism: CD20 antagonist
Expert: Monoclonal antibody targeting CD20 on B lymphocytes, causing B cell depletion
Everyday: Targets and depletes B cells that cause autoimmune damage
Targets: ["CD20"]
Revenue History
PeriodRevenue ($M)
2025$3,600M
Q4 2024$780M
Q4 2025$980M
2024$3,200M
Programs (2)
IndicationStageKey StudyRegional Status
Relapsing MSAPPROVEDASCLEPIOS I/II[{"stage":"APPROVED","region":"US","approval_date":"2020-08"}]
RMSAPPROVEDASCLEPIOS I/II[{"stage":"APPROVED","region":"US","approval_date":"2020-08-20"},{"stage":"APPRO
Notes
Anti-CD20 for MS. First self-administered B-cell therapy. Taking share from Ocrevus.
Data from Supabase · Updated 2026-03-24